ArticleOncology reports2026
Mechanistic study of MUC3A in promoting progression of clear cell renal cell carcinoma via the JAK‑STAT pathway.
Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer and is associated with poor prognosis. The present study identified a membrane‑associated mucin, mucin 3A (MUC3A), a transmembrane glycoprotein, as a novel oncogenic factor in ccRCC. MUC3A was found to be highly expressed in ccRCC tissues and cell lines, with elevated levels associated with worse patient survival. Functional assays demonstrated that MUC3A knockdown significantly inhibited cell proliferation, migration, invasion, and promoted apoptosis. Mechanistically, MUC3A activated the Janus kinase‑signal transducer and activator of transcription (JAK‑STAT) signaling pathway, and activation of STAT3 reversed the effects of MUC3A knockdown. These findings suggest that MUC3A facilitates ccRCC progression via JAK/STAT signaling and may serve as a potential prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.